394 related articles for article (PubMed ID: 16206603)
1. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
[TBL] [Abstract][Full Text] [Related]
2. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study].
Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN
Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264
[TBL] [Abstract][Full Text] [Related]
3. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
[TBL] [Abstract][Full Text] [Related]
4. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
6. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Yasumura Y; Miyatake K; Okamoto H; Miyauchi T; Kawana M; Tsutamoto T; Kitakaze M; Matsubara H; Takaoka H; Anzai T; Himeno H; Yokoyama H; Yokoya K; Shintani U; Hashimoto K; Koretsune Y; Nakamura Y; Imai K; Maruyama S; Masaoka Y; Sekiya M; Shiraki T; Shinohara H; Ozono K; Matsuoka T; Miyao Y; Nomura F
Circ J; 2004 Apr; 68(4):361-6. PubMed ID: 15056835
[TBL] [Abstract][Full Text] [Related]
8. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
9. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
10. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
[TBL] [Abstract][Full Text] [Related]
11. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
De Tommasi E; Iacoviello M; Romito R; Ceconi C; Guida P; Massari F; Francolini G; Bertocchi F; Ferrari R; Rizzon P; Pitzalis MV
Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes.
Shimoni Y
J Physiol; 2001 Nov; 537(Pt 1):83-92. PubMed ID: 11711563
[TBL] [Abstract][Full Text] [Related]
14. Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension.
Sakata K; Yoshida H; Obayashi K; Ishikawa J; Tamekiyo H; Nawada R; Doi O
J Hypertens; 2002 Jan; 20(1):103-10. PubMed ID: 11791032
[TBL] [Abstract][Full Text] [Related]
15. Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels.
Endlich K; Steinhausen M
J Hypertens; 1997 Jun; 15(6):633-41. PubMed ID: 9218183
[TBL] [Abstract][Full Text] [Related]
16. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure.
Squire IB; Macfadyen RJ; Lees KR; Hillis WS; Reid JL
Br J Clin Pharmacol; 1994 Aug; 38(2):117-23. PubMed ID: 7981011
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
18. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
[TBL] [Abstract][Full Text] [Related]
19. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
20. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
